Oral Nanoparticle Delivery of KPV Tripeptide Effectively Treats Ulcerative Colitis

Ulcerative colitis (UC) is a debilitating, chronic inflammatory bowel disease characterized by widespread inflammation and ulceration of the colon, leading to severe symptoms like abdominal pain, bloody diarrhea, and weight loss. Current therapeutic strategies, including corticosteroids and biologics, often come with significant systemic side effects or fail to achieve sustained remission due to poor drug delivery to the inflamed intestinal tissue. There is a critical and unmet clinical need for innovative, targeted, and orally administered therapies that can effectively deliver therapeutic agents directly to the inflamed colon while minimizing systemic exposure and improving patient compliance.

The KPV-HA-NPs significantly improved disease outcomes compared to free KPV or untreated controls, demonstrating superior therapeutic efficacy. > Oral delivery of KPV-HA-NPs resulted in a 65% reduction in the Disease Activity Index (DAI, a composite measure of colitis severity) compared to untreated DSS mice (p<0.001), indicating a substantial alleviation of colitis symptoms. Colon length, a key marker of inflammation and tissue damage, was significantly preserved, showing a 25% increase in KPV-HA-NP treated mice compared to DSS controls (p<0.01). Histological scores for inflammation and tissue damage were dramatically reduced by 70% (p<0.001). Furthermore, KPV-HA-NPs significantly suppressed pro-inflammatory cytokines, with TNF-α levels decreased by 55% and IL-6 by 48% in colonic tissue (p<0.05 for both), demonstrating potent anti-inflammatory effects at the molecular level.